The NTNG2 antibody targets Netrin-G2 (NTNG2), a member of the netrin family of axon guidance proteins. Unlike classical netrins, NTNG1 and NTNG2 are glycosylphosphatidylinositol (GPI)-anchored cell membrane proteins predominantly expressed in the central nervous system. NTNG2 is enriched in thalamocortical and corticothalamic projections, playing a critical role in establishing neural connectivity during development. It interacts with its receptor, LRRC4C (also known as NGL-1), to regulate synapse formation, maintenance, and plasticity. Dysregulation of NTNG2 signaling has been implicated in neurodevelopmental disorders, including schizophrenia and autism spectrum disorders (ASD). Antibodies against NTNG2 are essential tools for studying its expression patterns, subcellular localization, and function in both healthy and diseased states. They are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to visualize NTNG2 distribution in brain tissues or cultured neurons. Recent studies also utilize NTNG2 antibodies to explore its potential as a biomarker or therapeutic target in neurological conditions. Researchers prioritize antibodies with high specificity and validated cross-reactivity across species (e.g., human, mouse) to ensure experimental reproducibility.